Newly published trial data show cognitive gains in early patients and hint at disease-modifying effects, as Annovis moves towards validation.
Big expectations, followed by quiet disappointments. That’s how Alzheimer’s research has been. When Annovis Bio recently published its Phase 2/3 trial results for buntanetap in Nature NPJ Dementia, the headline outcome, “missing its primary endpoints,” might seem familiar. But this is one of those studies that reads differently the second time around.
Beneath the top-line result is a more specific and arguably more important story about who benefits, when and why that might matter for the future of aging itself.
The trial followed 351 people with mild to moderate Alzheimer’s over 12 weeks, testing three doses of buntanetap against a placebo. Not every participant had the same biological form of the disease, a detail that turned out to be crucial [1].
Among patients in earlier stages who tested positive for a biomarker called pTau217, the drug showed statistically significant improvements in cognition. Put simply, people in this subgroup were thinking more clearly, remembering better and declining more slowly than those not taking the drug.
Alzheimer’s is no longer seen as a single condition with a one-size-fits-all solution. It’s increasingly understood as a collection of overlapping pathologies. In that context, a drug that works well in a clearly defined group is not a failure; it’s a sign that the field is finally getting more precise.
What makes buntanetap different is its strategy. Most Alzheimer’s drugs focus on one toxic protein at a time. Buntanetap, by contrast, works earlier in the chain of events – blocking the production of several harmful proteins before they can build up and damage brain cells. A useful way to think about it: instead of mopping the floor again and again, it is trying to fix the leak.
In the study, patients taking buntanetap showed reductions in multiple biological markers linked to Alzheimer’s progression:
- Proteins like tau and TDP-43, which are associated with neuron damage
- Signals of inflammation in the brain
- Indicators of ongoing neurodegeneration
These changes hint at a deeper impact on the disease process itself. That’s the difference between treating Alzheimer’s and potentially reshaping its trajectory.
Then there’s the question every patient and investor eventually asks: does it come at a cost? So far, buntanetap appears to avoid the trade-offs that have complicated other Alzheimer’s treatments. It was safe and well-tolerated across all doses, including among ApoE4 carriers, a group genetically more vulnerable to the disease.
Even more practical, patients didn’t have to stop their existing medications to take it. In real-world care, that kind of flexibility can matter as much as efficacy.
One of the more revealing details in the study is also one of the least talked about: around 40% of participants did not show the biological markers typically associated with Alzheimer’s. In other words, a significant portion of the trial may not have had the kind of disease the drug is designed to treat.
That’s not just a quirk of this study; it’s a reflection of where Alzheimer’s medicine still struggles. Diagnosis has long relied on symptoms rather than biology. However, as treatments become more targeted, that approach is starting to show its limits.
What this trial suggests, indirectly, is that the future of Alzheimer’s care will depend as much on identifying the right patients as it does on developing the right drugs.
Annovis is now moving forward with a pivotal Phase 3 trial focused specifically on patients who fit the profile where buntanetap performed best: those in earlier stages with confirmed biomarkers.
The study will follow participants for longer, up to 18 months, to see whether the early cognitive improvements translate into sustained benefits, and whether the biological changes observed so far can truly slow disease progression. With 80% of patients already enrolled, the next chapter is already underway.
As Dr Cheng Fang, Senior Vice President, Research & Development, noted, “The data reinforce what we have seen across multiple studies: buntanetap addresses the underlying pathology of AD with a safety profile that supports its use in a broad, genetically diverse patient population.”
Moreover, buntanetap’s story fits into a larger longevity narrative. Alzheimer’s, more than most conditions, cuts directly against that goal. It erodes memory, autonomy and identity long before it shortens lifespan. What’s emerging now is a new kind of approach: earlier intervention, biomarker-driven treatment and therapies designed to act on the root causes of disease, not just its symptoms.
Buntanetap is not a finished story. The Phase 3 trial will ultimately determine whether its promise holds up. But even at this stage, it reflects something the field has been moving toward for years: a more precise, more layered understanding of how we age and how we might intervene before decline becomes inevitable.
